Full-Service Client Support For A Late Clinical-Stage Oncology Biotech

Catalyst Oncology played a pivotal role in salvaging a Phase III clinical trial for ovarian cancer after a large CRO's failure to meet critical milestones. This trial encompassed around 400 patients across 136 sites in 12 countries, necessitating rapid and effective intervention.

Leveraging its prior relationship with the biotechnology company, Catalyst provided comprehensive CRO services, including project and data management, and assembled a dedicated study team within just two weeks. Learn more about how Catalyst ensured the trial's timely completion, achieving successful patient enrollment, a prompt database lock, and the swift delivery of topline results, all primed for regulatory submission. This case underscores Catalyst's expertise in crisis management and its commitment to advancing oncology research through effective clinical trial support.